Axonics Modulation Technologies Inc (AXNX)vsJohnson & Johnson (JNJ)
AXNX
Axonics Modulation Technologies Inc
$0.43
-12.47%
HEALTHCARE · Cap: $3.63B
JNJ
Johnson & Johnson
$259.40
+2.19%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 22899% more annual revenue ($99.33B vs $431.90M). JNJ leads profitability with a 16.2% profit margin vs -1.3%. JNJ earns a higher WallStSmart Score of 57/100 (C).
AXNX
Hold36
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AXNX.
Margin of Safety
-76.5%
Fair Value
$143.78
Current Price
$259.40
$115.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 845.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.8% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Strong operational efficiency at 25.1%
Generating 3.4B in free cash flow
Areas to Watch
Negative free cash flow — burning cash
Currently unprofitable
Operating margin of -2.4%
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AXNX
The strongest argument for AXNX centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 24.8% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : AXNX
The primary concerns for AXNX are Free Cash Flow, Profit Margin, Operating Margin.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
AXNX profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
AXNX carries more volatility with a beta of 0.83 — expect wider price swings.
AXNX is growing revenue faster at 24.8% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 36/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Axonics Modulation Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
Axonics, Inc., a medical technology company, is dedicated to the development and commercialization of sacral neuromodulation (SNM) systems. The company is headquartered in Irvine, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?